-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Non-motor symptoms (NMS) of Parkinson's disease (PD) include autonomic nervous system dysfunction, loss of smell, mood and cognitive impairment, and sleep problems such as insomnia, daytime sleepiness, or rapid eye movement (REM) sleep behavior disorder.
The researchers randomly sampled 47 PD patients with stable motor symptoms and a disordered NMS defined by an MDS-UPDRS-I score ≥ 4 points.
Between October 2017 and July 2019, 19 patients received nabirone (median dose = 0.
In summary, the results of this study emphasize the potential efficacy of nabirone for PD patients with disordered NMS, which seems to be related to improving patients' anxiety and night sleep problems.
Original source:
Marina Peball, et al.
ncbi.
Leave a message here